Alvotech (NASDAQ: ALVO) announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) vial. The filing represents a significant step in Alvotech's biologics pipeline and signals continued regulatory momentum for biosimilar alternatives in the inflammatory bowel disease category.
Vedolizumab is a gut-selective integrin antagonist that works by blocking the α4β7 integrin receptor, reducing lymphocyte trafficking to the gastrointestinal mucosa. As a targeted mechanism with demonstrated efficacy in Crohn's disease and ulcerative colitis, it has become a cornerstone biologic therapy. An interchangeable designation — the regulatory threshold AVT16 is pursuing — would allow pharmacists in many U.S. states to substitute AVT16 for the reference product without prescriber intervention, a distinction that carries meaningful commercial weight compared to standard biosimilar status.
The IBD therapeutics market has drawn increasing attention from the functional nutrition and nutraceutical sectors as the gut-health category continues to expand. Gastroenterologists and integrative practitioners managing IBD patients often layer probiotic, prebiotic, and anti-inflammatory finished formulations alongside biologic therapy, making biosimilar approvals a downstream signal for the gut-health supplement space. Broader patient access to biologics can expand the population actively managing gut inflammation — a consumer cohort with documented interest in adjunctive nutritional support.
Alvotech, headquartered in Reykjavik with global manufacturing operations, has built its pipeline around high-complexity biologics targeting inflammation and autoimmune conditions. The company's co-manufacturing and white-label biologics strategy positions AVT16 as part of a broader portfolio play. FDA acceptance of the BLA initiates the formal review clock; a Prescription Drug User Fee Act (PDUFA) action date is expected to be communicated in subsequent filings. Operators and formulators tracking regulatory developments in anti-inflammatory ingredients should note that biosimilar market entry typically exerts downward pricing pressure on originator biologics, which can shift managed-care formulary dynamics and patient out-of-pocket costs.
While AVT16 sits firmly in the pharmaceutical biosimilar category rather than the dietary supplement channel, its regulatory trajectory is relevant context for nutraceutical brand owners positioning products within the gut-health and inflammation-management space. Increased clinical legitimacy around gut-targeted biologics tends to elevate consumer and practitioner awareness of the gut-immune axis broadly — a tailwind for science-backed functional ingredients addressing similar physiological pathways.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.